Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
SF Cook
Observed names:
S. COOK,
S. F. COOK
Institution:
GlaxoSmithKline (United States)
Observed institution:
GlaxoSmithKline (United States)
OpenAlex ID:
A5111655362
Gastrointestinal side effects in chronic opioid users: results from a population‐based survey
2008
·
S. F. COOK
, L. LANZA
, et al.
·
Alimentary Pharmacology & Therapeutics
·
144
Determinants of healthcare‐seeking behaviour among subjects with irritable bowel syndrome
2006
·
R. E. WILLIAMS
, C. L. BLACK
, et al.
·
Alimentary Pharmacology & Therapeutics
·
75
Stability of irritable bowel syndrome using a Rome II‐based classification
2005
·
R. E. WILLIAMS
, C. L. BLACK
, et al.
·
Alimentary Pharmacology & Therapeutics
·
39
PDF
A patient follow‐up survey programme for alosetron: assessing compliance to and effectiveness of the risk management programme
2006
·
D. MILLER
, L. BENNETT
, et al.
·
Alimentary Pharmacology & Therapeutics
·
20
The relationship between dosing of alosetron and discontinuation patterns reported by patients participating in a follow‐up programme
2007
·
P. TENNIS
, E. ANDREWS
, et al.
·
Alimentary Pharmacology & Therapeutics
·
10
PDF
Follow-up of an IBS cohort describes instability of C-IBS and D-IBS subtypes after three years
2005
·
RE Williams
, SF Cook
, et al.
·
1
Pmd28 Using a Web-panel to Aid Definition of a Target Patient Population to Assist Risk Management
2004
·
SC Eaton
, SF Cook
, et al.
·
Value in Health
·
1
Population-based survey of people with IBS: Frequency vs. consistency of bowel symptoms and reasons for health care seeking
2005
·
RE Williams
, SF Cook
, et al.
·
Gastroenterology
Development and Implementation of Risk Management Program for LOTRONEX (Alosetron HCL)
2004
·
Elizabeth Andrews
, SF Cook
, et al.
Show more works
View as search
Works count:
9
Citation count:
290
H-index:
5
I10-index:
5
Year
Topic
Type